A 48-year-old woman with a history of BRCA1 mutation undergoes screening ultrasound and is found to have a 3 cm complex ovarian mass with ascites and elevated CA-125 (450 U/mL). Which feature best distinguishes high-grade serous ovarian cancer from mucinous ovarian cancer in this clinical context?

Explanation

## High-Grade Serous vs. Mucinous Ovarian Cancer: Molecular and Clinical Discriminators ### Key Distinguishing Feature **High-Yield:** High-grade serous ovarian cancer (HGSOC) is strongly associated with BRCA1/BRCA2 germline mutations and TP53 alterations, whereas mucinous ovarian cancer (MOC) is not. This molecular signature is the most reliable discriminator in a BRCA-positive patient. ### Comparative Table | Feature | High-Grade Serous OC | Mucinous OC | |---------|----------------------|-------------| | **BRCA1/BRCA2 association** | 10–15% of cases; strong link | <1%; no significant association | | **TP53 mutations** | ~96% of HGSOC | ~10% of MOC | | **KRAS mutations** | ~5% | ~40–50% | | **Histology** | Serous epithelium, high mitotic rate, nuclear atypia | Mucin-producing epithelium, lower grade | | **Borderline/low-grade precursor** | Rare; usually de novo high-grade | Common; often preceded by borderline tumor | | **Stage at diagnosis** | 70–80% stage III–IV | 60–70% stage I–II | | **Response to platinum-based chemotherapy** | Excellent (homologous recombination deficiency) | Poor | | **5-year survival (stage III)** | ~40% | ~30% | ### Clinical Pearl **Key Point:** In a BRCA1-positive patient with ovarian cancer, the finding of HGSOC is expected and carries a specific therapeutic implication: these tumors are platinum-sensitive and benefit from PARP inhibitors (olaparib, niraparib) due to homologous recombination deficiency. Mucinous cancers do not harbor BRCA mutations and do not respond to PARP inhibitors. ### Mnemonic: BRCA-Serous Link **"BRCA loves HGSOC"** — BRCA mutations are a hallmark of high-grade serous ovarian cancer, not mucinous. HGSOC is the "BRCA-associated" epithelial ovarian cancer subtype. ### Pathologic Distinction ```mermaid flowchart TD A[Ovarian Cancer Suspected]:::outcome --> B{Histology?}:::decision B -->|Serous epithelium + high atypia| C[High-Grade Serous OC]:::outcome B -->|Mucin-producing epithelium| D[Mucinous OC]:::outcome C --> E{BRCA testing?}:::decision D --> F{BRCA testing?}:::decision E -->|Positive| G[BRCA1/BRCA2 mutation likely]:::action E -->|Negative| H[Sporadic HGSOC; TP53 mutation]:::action F -->|Positive| I[Rare; reassess diagnosis]:::urgent F -->|Negative| J[Typical mucinous OC; KRAS mutation likely]:::action ``` [cite:Robbins 10e Ch 22] [cite:Harrison 21e Ch 297]